Skip to main content
. 2010 Sep 1;202(Suppl 1):S108–S115. doi: 10.1086/653578

Figure 3.

Figure 3.

Two-way sensitivity analysis of the Rotarix program incremental cost-effectiveness ratio (ICER) on vaccine efficacy and market price per dose. The ICER estimates are determined under the assumption that under-2 rotavirus-associated mortality is at its lowest potential value of 0.0084. Combinations of price and efficacy highlighted in the hatched area would result in an ICER <$312 per disability-adjusted life-year averted.